Navigation Links
Upsher-Smith Announces Milestone in Development of CNS Strategy
Date:12/3/2009

MAPLE GROVE, Minn., Dec. 3 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the next phase of its strategic plan for central nervous system (CNS) diseases with USL255 (extended release topiramate), an internally developed program for the management of epilepsy. USL255 is being developed with Upsher-Smith's proprietary formulation technology and will enter a phase III clinical trial in early 2010 for the adjunctive treatment of epilepsy patients with partial onset seizures. USL255 is designed to provide convenient once daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.

"Upsher-Smith's goal is to build our leadership position in the CNS field through three complementary strategies including: alliances and co-development agreements; leveraging development of our core competency in formulation development; and actively pursuing licensing and acquisitions," said Mark Evenstad, President of Upsher-Smith.

The USL255 program for epilepsy builds on Upsher-Smith's other CNS program, PRX1 for the symptomatic treatment of Parkinson's disease. PRX1 is a co-development program with Proximagen Neuroscience, a biopharmaceutical company focused on CNS diseases. In July 2008, Upsher-Smith entered into a worldwide licensing agreement covering the development and commercialization of Proximagen's proprietary PRX1 program.

"The clinical development of USL255 and the PRX1 program with Proximagen are in line with Upsher-Smith's vision to become a leader in providing therapies that empower people suffering from CNS diseases to lead healthy, productive lives," said Evenstad. "These two milestones demonstrate our core competencies and commitment to bringing the highest quality pharmaceuticals to patients for more than eight decades."

About Epilepsy and Parkinson's Disease

Epilepsy is a neurological condition that produces seizures affecting a variety of mental and physical functions. Almost three million people in the U.S. have some form of active epilepsy with about 200,000 new cases of epilepsy diagnosed each year.[1] Parkinson's disease is a chronic, progressive neurodegenerative disease that causes impairment in motor function, as well as many non-motor complications throughout the various stages of the disease. As many as 1 million people in the U.S. suffer from Parkinson's disease, with 1 in 100 people over the age of 60 affected. [2]

About Upsher-Smith

Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit www.upsher-smith.com.

Source:

[1]. Epilepsy Foundation. Available at: http://www.epilepsyfoundation.org/about/. Accessed on November 18, 2009

[2]. National Parkinson Foundation. Available at: http://www.parkinson.org/Page.aspx?pid=225. Accessed on November 18, 2009

SOURCE Upsher-Smith Laboratories, Inc.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
2. Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products
3. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
4. Varian, Inc. Announces Form 10-K Filing
5. Jupiter Medical Center Announces New High-Definition MRI System
6. TeamHealth Teleradiology Announces New Contracts in South Carolina and Illinois
7. Cardio Vascular Medical Device Announces Forward Stock Split
8. PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share
9. Clarient Announces CFO Transition Plan
10. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
11. AMT Announces Management Changes in Light of Refocused Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017 Infusion ... devices used for administering medications in a controlled, ... used for therapeutic purposes in critical care, pain ... required to make patient,s feel comfortable and pain ... errors which would lead to serious life threatening ...
(Date:1/16/2017)... 2017 Derek H. Potts , founder ... recently appointed Liaison Counsel in California,s ... cases. In this role, Potts was assigned to serve ... assist the Court and Co Lead Plaintiff,s Counsel. Co-Counsel ... Jackson Fairchild & Wade and Ruth Rizkalla ...
(Date:1/16/2017)... TORONTO , Jan. 16, 2017 When synthetic ... to market their product as top-rate. They offered free samples, ... top-notch customer service. Soon, business was booming. ... often described as 100 times more powerful than morphine, has ... in last 2 years. One dealer,s recorded fentanyl ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. Behzad ... offering complimentary consultations and financing for orthodontics for a limited time. Complimentary for ... learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Specialty Technical Publishers (STP) ... Audit Protocol Consortium (IAPC) EHS audit protocol for Singapore . Leading companies ... their EHS regulatory obligations and rapidly collect, share, archive, and export audit findings ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, ... to her nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, ...
(Date:1/16/2017)... ... 2017 , ... One thing common to all types of cancer is that ... well. The money spent screening for and treating cancer in the United States is ... cancer more than in any other country that has an advanced healthcare system, sometimes ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected as ... organizations honored for their accomplishments in the field of midmarket financial software. , Members ... recognition, and innovation. Selection is not based on revenue and those firms chosen represent ...
Breaking Medicine News(10 mins):